Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Pembrolizumab for High-risk Stage II Melanoma
Recruiting1 awardPhase 3
Ottawa, Ontario
This trial will evaluate the safety and efficacy of pembrolizumab compared to placebo in participants with surgically resected high-risk Stage II melanoma. The primary hypothesis is that pembrolizumab increases recurrence-free survival.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.